A Retrospective Review of Thiazolidinediones with Development of a Troglitazone Conversion Protocol

The objective of this paper was (1) to assess compliance with the National Veterans Affairs Guidelines for the use of troglitazone and rosiglitazone and (2) to develop and implement a conversion protocol that allows effective management of patients receiving troglitazone. A retrospective chart revie...

Full description

Saved in:
Bibliographic Details
Main Authors: Cameron Lindsey, Maqual Graham, Julie McMurphy
Format: Article
Language:English
Published: Wiley 2003-01-01
Series:The Scientific World Journal
Online Access:http://dx.doi.org/10.1100/tsw.2003.37
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832563085103071232
author Cameron Lindsey
Maqual Graham
Julie McMurphy
author_facet Cameron Lindsey
Maqual Graham
Julie McMurphy
author_sort Cameron Lindsey
collection DOAJ
description The objective of this paper was (1) to assess compliance with the National Veterans Affairs Guidelines for the use of troglitazone and rosiglitazone and (2) to develop and implement a conversion protocol that allows effective management of patients receiving troglitazone. A retrospective chart review was conducted to assess adherence to guidelines for all patients receiving troglitazone and rosiglitazone at the medical center. Appropriateness of therapy through indication evaluation, safety through alanine aminotransferase (ALT) monitoring compliance, and efficacy through hemoglobin A1c (HbA1c) changes were used to assess adherence. According to National Veterans Affairs (VA) Guidelines, 68% of troglitazone and 63% of rosiglitazone patients had an appropriate indication for the use of these agents. Baseline ALT levels were obtained in 40% of troglitazone and 71% of rosiglitazone patients. Full compliance with continual ALT monitoring was seen in 6 and 54% of patients, respectively. Goal HbA1c was achieved in 57 and 29% of patients, respectively. Of the 33 patients receiving troglitazone, 19 were converted to rosiglitazone therapy; 11 were maintained on current regimens without troglitazone, and 3 were lost to follow up. Adherence to guidelines needs to be reinforced, in particular, compliance with ALT monitoring. However, there were no reported cases of hepatotoxicity in the patients reviewed. Many patients did not achieve a HbA1c
format Article
id doaj-art-69026c599322415e95f69bee658f3f4a
institution Kabale University
issn 1537-744X
language English
publishDate 2003-01-01
publisher Wiley
record_format Article
series The Scientific World Journal
spelling doaj-art-69026c599322415e95f69bee658f3f4a2025-02-03T01:20:57ZengWileyThe Scientific World Journal1537-744X2003-01-01347748310.1100/tsw.2003.37A Retrospective Review of Thiazolidinediones with Development of a Troglitazone Conversion ProtocolCameron Lindsey0Maqual Graham1Julie McMurphy2University of Missouri-Kansas City School of Pharmacy, MO 64108, USAUniversity of Missouri-Kansas City School of Pharmacy, MO 64108, USAUniversity of Missouri-Kansas City School of Pharmacy, MO 64108, USAThe objective of this paper was (1) to assess compliance with the National Veterans Affairs Guidelines for the use of troglitazone and rosiglitazone and (2) to develop and implement a conversion protocol that allows effective management of patients receiving troglitazone. A retrospective chart review was conducted to assess adherence to guidelines for all patients receiving troglitazone and rosiglitazone at the medical center. Appropriateness of therapy through indication evaluation, safety through alanine aminotransferase (ALT) monitoring compliance, and efficacy through hemoglobin A1c (HbA1c) changes were used to assess adherence. According to National Veterans Affairs (VA) Guidelines, 68% of troglitazone and 63% of rosiglitazone patients had an appropriate indication for the use of these agents. Baseline ALT levels were obtained in 40% of troglitazone and 71% of rosiglitazone patients. Full compliance with continual ALT monitoring was seen in 6 and 54% of patients, respectively. Goal HbA1c was achieved in 57 and 29% of patients, respectively. Of the 33 patients receiving troglitazone, 19 were converted to rosiglitazone therapy; 11 were maintained on current regimens without troglitazone, and 3 were lost to follow up. Adherence to guidelines needs to be reinforced, in particular, compliance with ALT monitoring. However, there were no reported cases of hepatotoxicity in the patients reviewed. Many patients did not achieve a HbA1chttp://dx.doi.org/10.1100/tsw.2003.37
spellingShingle Cameron Lindsey
Maqual Graham
Julie McMurphy
A Retrospective Review of Thiazolidinediones with Development of a Troglitazone Conversion Protocol
The Scientific World Journal
title A Retrospective Review of Thiazolidinediones with Development of a Troglitazone Conversion Protocol
title_full A Retrospective Review of Thiazolidinediones with Development of a Troglitazone Conversion Protocol
title_fullStr A Retrospective Review of Thiazolidinediones with Development of a Troglitazone Conversion Protocol
title_full_unstemmed A Retrospective Review of Thiazolidinediones with Development of a Troglitazone Conversion Protocol
title_short A Retrospective Review of Thiazolidinediones with Development of a Troglitazone Conversion Protocol
title_sort retrospective review of thiazolidinediones with development of a troglitazone conversion protocol
url http://dx.doi.org/10.1100/tsw.2003.37
work_keys_str_mv AT cameronlindsey aretrospectivereviewofthiazolidinedioneswithdevelopmentofatroglitazoneconversionprotocol
AT maqualgraham aretrospectivereviewofthiazolidinedioneswithdevelopmentofatroglitazoneconversionprotocol
AT juliemcmurphy aretrospectivereviewofthiazolidinedioneswithdevelopmentofatroglitazoneconversionprotocol
AT cameronlindsey retrospectivereviewofthiazolidinedioneswithdevelopmentofatroglitazoneconversionprotocol
AT maqualgraham retrospectivereviewofthiazolidinedioneswithdevelopmentofatroglitazoneconversionprotocol
AT juliemcmurphy retrospectivereviewofthiazolidinedioneswithdevelopmentofatroglitazoneconversionprotocol